Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -52.34% is 45% above its 5-year average of -94.89%, near the high end of its 5-year range (-230.55%–-23.37%).
4.60% above its 12-month average of -54.87%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -36.10%.
RETURN ON ASSETS (ROA)
-52.34%
RETURN ON ASSETS (ROA) AVG TTM
-54.87%
RETURN ON ASSETS (ROA) AVG 3Y
-41.09%
RETURN ON ASSETS (ROA) AVG 5Y
-94.89%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.60%
CURRENT VS 3Y AVG
-27.39%
CURRENT VS 5Y AVG
+44.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 777 covered companies
CURRENT VS SECTOR MEDIAN
-66.85%
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.98B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$1.98B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$1.96B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$2.02B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.04B
Return on Assets (ROA)
10.98%
TTM Avg
8.41%
3Y Avg
7.65%
5Y Avg
11.22%
Market Cap
$2.04B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$1.91B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$2.05B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.06B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.98B | -52.34% | -54.87% | -41.09% | -94.89% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 14.58% | 11.33% | 2.89% | -3.84% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | -11.00% | -5.98% | -9.46% | -10.43% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 39.65% | 19.63% | 0.51% | -8.90% |
| Progyny, Inc. (PGNY)vs › | $2.04B | 10.98% | 8.41% | 7.65% | 11.22% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | -68.96% | 16.60% | -13.89% | -23.58% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | -11.05% | -19.34% | -25.88% | -26.23% |
| Alvotech (ALVO)vs › | $2.05B | -11.31% | -8.55% | -34.29% | -31.66% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.06B | -3.14% | -22.75% | -10.43% | -6.58% |
| Immunome, Inc. (IMNM)vs › | $1.90B | -44.98% | -76.52% | -94.59% | -76.85% |
ROA
-52.3%
ROE
-63.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -23.37% |
| 2024-12-31 | -86.36% |
| 2023-12-31 | -28.57% |
| 2022-12-31 | -26.04% |
| 2021-12-31 | -174.45% |
| 2020-12-31 | -230.55% |
